• Bacterial infections

Vabomere Generic Name & Formulations

General Description

Meropenem, vaborbactam 2g/vial (containing meropenem 1g + vaborbactam 1g); pwd for IV infusion after reconstitution and dilution; sodium content 10.9mEq/vial; preservative-free.

Pharmacological Class

Carbapenem + beta-lactamase inhibitor.

How Supplied

Single-dose vials—6


Generic Availability


Vabomere Indications


Susceptible complicated urinary tract infections (cUTI) including pyelonephritis.

Vabomere Dosage and Administration


Give by IV infusion over 3hrs. ≥18yrs (eGFR ≥50mL/min/1.73m2): 4g every 8hrs. Renal impairment (eGFR 30–49mL/min/1.73m2): 2g every 8hrs; (eGFR 15–29mL/min/1.73m2): 2g every 12hrs; (eGFR <15mL/min/1.73m2): 1g every 12hrs. Give after hemodialysis session. All: treat for up to 14 days.


<18yrs: not established.

Vabomere Contraindications

Not Applicable

Vabomere Boxed Warnings

Not Applicable

Vabomere Warnings/Precautions


Previous hypersensitivity to penicillins, cephalosporins, other beta-lactams, or other allergens. Discontinue immediately if allergic reaction occurs. CNS disorders (eg, brain lesions, history of seizures). Bacterial meningitis. Renal impairment (thrombocytopenia possible). Reevaluate dose if focal tremors, myoclonus, or seizures occur. Discontinue if C. difficile-associated diarrhea suspected or confirmed. Pregnancy. Nursing mothers.

Vabomere Pharmacokinetics

See Literature

Vabomere Interactions


Concomitant valproic acid or divalproex sodium: not recommended; if use necessary, consider supplemental anticonvulsant. Potentiated by probenecid: not recommended.

Vabomere Adverse Reactions

Adverse Reactions

Headache, phlebitis/infusion site reactions, diarrhea; serious hypersensitivity reactions, C. difficile-associated diarrhea, possible neuromotor impairment (eg, seizures, delirium, paresthesias), superinfection.

Vabomere Clinical Trials

See Literature

Vabomere Note

Not Applicable

Vabomere Patient Counseling

See Literature